NuvOx Therapeutics (“NuvOx”), a clinical-stage biotechnology company developing oxygen therapeutics for life-threatening hypoxemic conditions, today announced positive preliminary results from the second cohort of its ongoing EXTEND Phase Ib clinical trial of NanO₂™ (dodecafluoropentane emulsion) in patients with mild respiratory distress.
The results demonstrated stronger oxygenation signals with dose escalation while maintaining an excellent safety profile. These findings will be presented both orally and in a poster form at the 2026 Respiratory Innovation Summit (RIS) as part of the ATS 2026 International Conference.